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Abstract 
Glioblastoma (GB), the most common and aggressive adult brain tumor, is characterized by extreme 
phenotypic diversity and treatment failure. Through fluorescence-guided resection, we identified 
fluorescent tissue in the sub-ependymal zone (SEZ) of GB patients. Histological analysis and molecular 
characterization revealed that the SEZ harbors malignant cells with tumor-initiating capacity, 
analogous to cells isolated from the fluorescent tumor mass (T). We observed resistance to supra-
maximal chemotherapy doses along with differential patterns of drug response between T and SEZ in 
the same tumor. Our results reveal novel insights into the GB growth dynamics, with implications for 
understanding and limiting treatment resistance. 
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Introduction 
The basis of phenotypic diversity and treatment failure in human GB is poorly understood. Murine 
models of gliomagenesis point to sub-ependymal neural stem cells (NSCs) as a putative cell of origin 
for astrocytic tumors. The stepwise pre-malignant loss of tumor suppressors p53, NF1 & PTEN (1, 2) 
has been shown to lead to the development of an aggressive disease characterized by resistance to 
genotoxic injury (3).  
Additionally, stratifying patients using transcriptional profiles derived from a large cohort of GB single 
tumor samples (4) has identified multiple disease subtypes, which may have prognostic significance (5, 
6). However, emerging data on genomic intra-tumor heterogeneity in GB indicate spatial segregation of 
genetically distinct clones in the same tumor (7), making the interpretation of single-sample tumor data 
challenging. Importantly, this may contribute to the pervasive failure of treatment in GB patients. 
 
Clinical trials have established that use of a fluorescence biomarker, 5-aminolevulinic acid (5-ALA), 
can enhance the surgical resection of GB (8). We have demonstrated the use of 5-ALA in a 
Fluorescence-Guided Multiple Sampling (FGMS) strategy that permits real-time spatially segregated 
tumor sampling during surgery (7, 9). Combining visible fluorescence with neuroanatomy allows for 
the objective distinction of the tumor mass T (visible fluorescent). Importantly, a spatially distinct and 
visibly fluorescent sub-ependymal zone (SEZ) can also be identified in a subset of GB patients. 
 
Here we report an integrated genomic analysis of SEZ and T samples, obtained by FGMS, which 
reveals that malignant cells in the SEZ contribute to tumor growth. Functional characterization 
confirms that the SEZ contains tumor-initiating cells (TICs) that can recapitulate the disease in 
orthotopic patient-derived xenogeneic models in a manner similar to TICs isolated from the 
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corresponding T. TICs in the SEZ contribute to resistance to chemotherapy and show differential 
patterns of response when compared to T of the same patients. 
 
Materials and Methods  
GB sample collection 
Patient informed consent was obtained through our research clinic (10). Tissue collection protocols 
were compliant with the UK Human Tissue Act 2004 (HTA Licence ref 12315) and approved by the 
Local Regional Ethics Committee (LREC ref 04/Q0108/60). No difference in 5-ALA labeling capacity 
was observed among patients. See Supplementary Experimental Procedure for details on 5-ALA 
administration and sample collection. 
Quantitative Real-time PCR analysis 
Total RNA was extracted from T and SEZ tissues using TRIzol (Invitrogen) according to the 
manufacturer's instructions. RNA was treated with DNase (Qiagen) and cDNA was synthesized from 
5μg of total RNA using Random Primers (Invitrogen) and a Superscript III First-Strand Synthesis 
System for real-time PCR (RT–PCR) (Invitrogen). The RT–PCR for Nestin, Gfap, Sox2 and MIB1 
transcripts was performed using CFX96 RT–PCR (Biorad), RT2 qPCR Primer Assay and SYBR Green 
Master Mix (Qiagen) according to the manufacturer's instructions. 18S was used as the housekeeping 
reference. Relative expression quantification was performed by the ΔΔCT method. Experiments were 
performed in triplicate and each experiment was repeated 3 times.  
Cell line derivation and implantation 
Cell cultures from T and SEZ of 42 patients were established from GB patients undergoing surgery at 
Addenbrooke’s Hospital, Cambridge, in 2010-2012. The cells were isolated  as described (9, 11, 12) 
and used either uncultured (primary) or propagated in vitro for 2 passages (briefly cultured) in serum-
free medium. The U87 cell line was obtained from the American Type Culture Collection, cultured 
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according to the supplier’s recommendations and used just after resuscitation. Tissue collection to 
establish HFNSCs was approved by the Local Regional Ethics Committee. Cells were established in 
2011 and grown in serum-free medium in order to form neurospheres and used at early passage. All the 
cell cultures have been tested for mycoplasma contamination by PCR before use. See Supplementary 
Experimental Procedure for details on cell propagation, immunofluorescence and in vivo experiments. 
DNA and RNA extraction 
DNA from T and SEZ tissues of 14 GB patients was extracted for copy number analysis using DNeasy 
Blood & Tissue Kit (Qiagen). RNA from T and SEZ tissues of 15 GB patients was extracted for gene 
expression analysis using Trizol (Invitrogen) and cleaned up using MiniElute columns (Qiagen). See 
Supplementary Experimental Procedure for details on copy number and gene expression analysis. Copy 
number results were validated by fluorescence in situ hybridization as described in the Supplementary 
Experimental Procedure. 
Drug treatment assay 
Treatment with Temozolomide, Cisplatin and Cediranib was evaluated using the in vitro BrdU cell 
proliferation assay (Millipore). 3x103 cells were plated in triplicate per treatment condition. Control 
wells for Temozolomide, Cisplatin and Cediranib are shared as these treatments have been applied in 
the same experiments. One day after plating, the treatment was applied for 3 days. BrdU was applied in 
the final 24 hours of the treatment. Each experiment was repeated 3 times. See Supplementary 
Experimental Procedure for details on drug concentration. 
MGMT promoter methylation 
Analysis of MGMT promoter methylation was performed by PCR (13) and by pyrosequencing (14). In 
brief, DNA was bisulfite converted and subsequently subjected to PCRs using specific primer pairs for 
the methylated or the modified unmethylated DNA. PCR products were resolved in a 2% agarose gel 
stained with SybrSafe. See Supplementary Experimental Procedure for further details. 
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Phylogenetic reconstruction 
Multiple spatially separated samples taken from each GB were collected in order to reconstruct the 
phylogenetic relationship between the tumor and SEZ. See Supplementary Experimental Procedure for 
details on molecular clock analysis. 
Statistical analysis 
For in vivo experiments using Nod/Scid animals, we performed Kaplan-Meier survival analysis using 
the Logrank test for hypothesis testing.  
For drug response analysis using BrdU, a one-way ANOVA was performed for each patient.  
The p-values for the pairwise mean comparisons of each treatment to the corresponding control were 
calculated using Tukey’s Honestly Significant Difference test. In the related figures and for each 
patient, we plotted the normalized mean treatment response using the corresponding mean control as a 
reference, except in Supplementary Fig. 12, where we normalized to the mean of the 50µM TMZ 
treatment response. The minimum and maximum normalized values are provided in order to present 
the dispersion of the normalized data. 
 
Results 
SEZ harbors residual disease in GB patients 
We screened 65 GB patients given 5-ALA and confirmed that visibly fluorescent disease extended to 
the SEZ in 65% (42/65) of the cases. Multiple samples were obtained from 14 patients. Histological 
features of high-grade glioma (15) were detected in SEZ and T of the patients (Fig. 1A; additional two 
representative GBs are shown in Supplementary Fig. S1, A and B). SEZ tissue was also used to identify 
the ependymal layer and confirm correct sampling (Supplementary Fig. S2). 
 
GB has been shown to heterogeneously express glial fibrillary acidic protein (Gfap) (16) and consistent  
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with this we noted high expression of Gfap in SEZ samples compared to matched T samples (Fig. 1, B 
and C top panel and Supplementary Fig. S1C). Expression of the precursor marker Nestin was detected 
both in T and SEZ tissues (Fig. 1, B and C middle panel and Supplementary Fig. S1C). The SEZ 
showed increased vascularization in comparison to T, as determined by CD31 expression (Fig. 1, B and 
C bottom panel). Weak expression of the neuronal marker Tuj1 was observed in both areas 
(Supplementary Fig. S1C). One of the histological hallmarks of GB is high proliferative activity (17) 
and we observed similar numbers of mitotic cells in T and SEZ (MIB1 index 20.5±2.8 and 18.1±1.9 
respectively) (Supplementary Fig. S1C). The extent of focal necrosis was similar in T and SEZ of the 
same patients (except for sp40) (Supplementary Table S1). Consistent with immunohistochemical 
analysis, T and SEZ contained similar amounts of tumor tissue (except for sp54) (Supplementary Table 
S1). Together these data suggest that regulatory mechanisms promoting proliferation and 
vascularization are common to the T and the SEZ tissues.  
To confirm these findings we performed real-time analysis of gene expression for markers of glial and 
precursors cells (Gfap and Nestin), stem cells (Sox2), proliferation (MIB1) on T and SEZ tissues of 3 
GBs in total (Supplementary Fig. S3). Our results show increased expression of Gfap in the SEZ 
compared with the corresponding T (Supplementary Fig. S3). The expression of  Nestin and Sox2  
is similar between T and SEZ, except in sp10 for Sox2 (Supplementary Fig. S3). 
 
We applied high-throughput molecular profiling techniques to the SEZ and T to characterize each of 
these regions. DNA/RNA were extracted from the tissues of the 14 patients (Supplementary Table 
S2A). After quality assessment, we analyzed copy number aberrations (CNAs) of 8 patients and gene 
expression profiles of 9 patients (6 of whom were common to both analyses) (Supplementary Table 
S2B shows the patient clinical information). Our data reveal multiple aberrations (e.g. EGFR 
amplification and CDKN2A deletions) common to T and the corresponding SEZ in individual patients 
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(Fig. 2A and Supplementary Fig. S4). In 6/8 patients, the SEZ had an equal or smaller number of 
putative driver aberrations with respect to the corresponding T (mean difference in the number of 
aberrations is 1.27±0.38; p-value = 0.12). CNA results were validated by fluorescence in situ 
hybridization (FISH) for three GB drivers, EGFR, MET and PTEN (4), in three patients with available 
tissue (Fig. 2B and Supplementary Fig. S5, A-H). Because we observed in vitro aberrations in the 
corresponding cell cultures (Supplementary Fig. S6), we restricted further genomic analysis to tissue 
samples. 
 
Clustering of the gene expression data (18) revealed that only 3/9 paired samples (SEZ and T from the 
same patient) clustered tightly together while 5/9 SEZ were assigned to the same sub-cluster, 
suggesting a SEZ-specific expression profile across patients (Fig. 2C).  
 
We used a previously published classifier to assign our samples into one of 4 GB subtypes (6). 7/9 SEZ 
were classified as Mesenchymal (sp41, sp42, sp52, sp54, sp56, sp57 and r4) and the remaining 2 were 
Classical (sp49 and sp55). For 6/9 patients the SEZ was assigned to a different subtype than the 
corresponding T. T samples were distributed amongst the 4 subtypes (Classical, Mesenchymal, Neural 
and Proneural) (Fig. 2D).  
 
We next investigated whether gene expression levels differed between SEZ and T. We rejected the 
hypotheses of no significant differences in the expression levels of all genes between SEZ and T (p-
value <0.00001), which suggests that there are differentially expressed genes in SEZ and T. 
We next used the R package HDTD to identify gene ontology (GO) terms whose genes are 
differentially expressed (Supplementary Table S3).  
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Tumor-initiating cells reside in the SEZ  
We next extended the characterization of T and SEZ to TIC populations. In neuro-epithelial 
malignancies the purification of TICs remains challenging because no robust cell-surface marker has 
been identified to distinguish tumorigenic and non-tumorigenic cells (19, 20). Initial data identifying 
CD133/Prominin1 as a marker in human GB (21) were subsequently challenged both in primary and 
cultured TICs (reviewed in (19)). More recently the cell surface marker CD15/SSEA-1 has been 
identified as a possible TIC marker in GB and medulloblastoma (22, 23).  CD15 is a carbohydrate 
moiety expressed by neural stem and progenitor cells (24) but its use as GB marker did not find 
additional confirmation (25).  
We therefore used a marker-independent approach (9, 11, 12, 26) to isolate cells from T and SEZ under 
serum-free conditions in vitro (Fig. 3A). Growth curve analysis and limiting-dilution assays confirmed 
long-term self-renewal and expansion (Fig. 3B and Supplementary Fig. S7), clonogenicity and 
multipotency similar to the corresponding T cells (Supplementary Fig. S8).  
We evaluated the expression of the precursor marker Nestin and other putative TIC markers (A2B5,  
CD133, CD15) from T and SEZ (reviewed in (19)) and found similar expression of Nestin in T and 
SEZ cells, in agreement with the data  in Fig. 1, B and C. In contrast, A2B5-, CD133- and CD15-
positive cells were rarely found (Supplementary Fig. S9, A and B). 
 
Despite phenotypic differences in vitro, orthotopic inoculation of T and SEZ cells in NOD-SCID mice 
consistently generated tumors in all cases (Fig. 3, C and D and Supplementary Fig. S10). Nonetheless, 
a statistically significant shorter survival was observed for animals injected with T cells compared to 
those injected with SEZ cells (Fig. 3C and Supplementary Fig. S10; p-value <0.05).  
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To our knowledge, this is the first time that SEZ cells from GB patients have been tested for their 
tumorigenic potential. We analyzed the in vivo properties of enriched SEZ cells from 3 additional GBs. 
In all cases SEZ cells gave rise to tumors with similar patterns of growth and infiltration to those 
generated from TICs isolated from T under the same experimental conditions (Supplementary Fig. S11, 
A-C). 
 
TICs from the SEZ contribute to drug resistance 
The SEZ and T contained self-renewing TICs suitable for chemo-response assays. These cells are 
grown in conditions that better preserve the genotype of the original disease (27) and have been 
proposed for use in high-throughput drug screening (28, 29). We tested the effects of the oral alkylating 
agent Temozolomide (TMZ), the current standard of care in GB patients (30). To facilitate analysis, we 
assayed methylation in the promoter region of MGMT, a methyltransferase that inhibits the cytotoxic 
effect of TMZ and is a predictive biomarker in GB (31). 
 
We initially treated TICs isolated from T and SEZ of 7 GB patients with TMZ at maximum 
concentrations reported for the brain and plasma (50 μM) (32, 33), but no significant treatment 
response was observed relative to the corresponding controls (vehicle only). Only sp12 showed a 
significant response in both T and SEZ (Supplementary Fig. S12). We therefore analyzed a set of TICs 
isolated from T of 20 patients using a dose escalation strategy ranging from 50μM to 2.5mM of TMZ, 
and found that only 20% of the samples exhibited a significant response at ≥ 500 μM (Supplementary 
Fig. S13, A and B). 
Based on these results we performed cell proliferation assays for TMZ concentrations between 50 μM 
and 2.5mM on TICs isolated from T and SEZ of the same tumor for 8 patients. We noted that TICs 
continued to proliferate in the SEZ and T at supra-maximal drug concentrations. We also observed that 
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the response varied between T and SEZ of the same GB (Fig. 4A and Supplementary Fig. S14A). Three 
patterns emerged: differential response between T and SEZ (e.g. sp13, sp20, sp37 and sp42), both T 
and SEZ respond (e.g. sp17, sp23), neither T nor SEZ respond (e.g. sp14, except at 2.5 mM TMZ for T, 
and sp52).  
To test whether resistance to TMZ was MGMT-dependent, we analyzed the DNA methylation status of 
the MGMT promoter by pyrosequencing (Supplementary Table S4) and methylation-specific PCR (13) 
(Supplementary Fig. S15) and we found that the results were in agreement except for sp42.  
Our PCR analysis revealed that 4/7 paired TICs (sp14, sp23, sp37 and sp52) did not show methylation  
of the MGMT promoter in either the T or the SEZ consistent with the poor response to TMZ, except for  
sp23 (T and SEZ) and sp37T. In contrast, sp17, sp20 and sp42 are methylated and showed a better 
response to TMZ among all the tested TICs with the exception of sp20SEZ and sp42T (Fig. 4A and 
Supplementary Fig. S14A). All together, our results suggest that MGMT methylation status is 
homogeneous in T and SEZ of the same patients and generally predicts response to TMZ 
(Supplementary Table S5). 
 
We also evaluated the anti-mitotic agent Cisplatin, previously used in GB therapy, and Cediranib, an 
anti-angiogenic inhibitor of VEGFRs with additional activity against PDGFRB, recently used in 
clinical trials (34, 35) (Fig. 4B and Supplementary Fig. S14B). Although anti-angiogenic therapies 
target the endothelial compartment, it has been reported that VEGFRs are enriched on the surface of 
TICs from GB (36). VEGF signals via its endothelial tyrosine kinase receptor 2 (VEGFR2) (35), so we 
first confirmed that this receptor is expressed in TICs from T and SEZ (Supplementary Fig. S16). We 
next quantified the expression of VEGF and PDGF receptors. No significant difference was present 
between T and SEZ (no VEGFR1 nor VEGFR3 probe was available in the Illumina arrays) 
(Supplementary Table S6). 
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Exposure to Cisplatin and Cediranib revealed resistant TICs in T and SEZ together with a 
heterogeneous response profile (Fig. 4B and Supplementary Fig. S14B). Whereas sp17 and sp23 
showed sensitivity to these treatments in T and SEZ, a significant response was observed only in one of 
the two regions for sp13, sp20 and sp52 (Fig. 4B).  
 
The drug response profile of TICs from T and SEZ of the same patients emphasizes their potential 
utility in drug development compared to standard glioma cell lines e.g. U87 and human fetal neural 
stem cells (HFNSCs). U87 significantly responded to treatment with TMZ, Cisplatin and Cediranib 
whereas two HFNSCs lines (HFNSC and HFNSC1) were resistant to TMZ, as  previously reported (37)  
and to Cisplatin and Cediranib (Supplementary Fig. S17). 
 
Phylogenetic reconstruction suggests different patterns of GB evolution involving SEZ malignant  
cells 
Our genomic and chemo-response assays data show that the SEZ harbors malignant cells that 
contribute to tumor growth and murine models of GB indicate that the SEZ is enriched for tumor 
ancestors (2, 38-40). However, this has not been confirmed in GB patients. We analyzed SEZ and T 
samples to determine if tumor cells grow out of the SEZ or into the SEZ. We reconstructed tumor 
ancestral trees in 8 patients, using several genomic measurements derived from multiple spatially 
separated samples taken from the GB mass (T1-T6) and SEZ. We have previously employed this 
approach to describe intra-tumor heterogeneity in T and infer tumor evolution (7) and we now used 
FGMS to position the SEZ. In particular, we reconstructed phylogeny based on genome-wide DNA 
copy number (41). In an independent assay, we exploited the observation that cells record their 
ancestral history in the form of neutral DNA methylation patterns (42, 43). This analysis is not biased 
by the presence of non-neoplastic cells as only highly proliferative tissues accumulate sufficient 
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methylation events (tumors and colonic epithelium) (44) (Fig. 5A). We first validated the molecular 
clock loci chosen for this analysis (Fig. 5, B and C, top) and then calculated the normal cell content in 
SEZ and T. The values of cellularity indicate no significant difference (Fig. 5, B and C, bottom). 
 
These orthogonal techniques yielded highly concordant phylogenies: in sp52, sp54, sp56 and sp57, the 
SEZ harbors tumor precursor cells that gave rise to the GB mass (Fig. 5D). In sp42 and sp49, we 
observed a similar trend although the two methods are not in full agreement (Fig. 5D). Analysis of sp55 
and sp58 suggests a different pattern of evolution and emphasizes the heterogeneous nature of GB (Fig.  
5D). Taken together, these data suggest that the SEZ contains a reservoir of malignant cells that are  
either tumor precursor clones or clones generated during GB evolution. 
 
Discussion 
Our comprehensive phenotypic, genomic and functional analysis reveals residual disease in the SEZ of 
GB patients (Fig. 1A and Supplementary Fig. S1, A and B). TICs are present in T and SEZ of the same 
GBs (Fig. 3C and Supplementary Fig. S10) and show differential patterns of therapeutic responsiveness 
and drug resistance (Fig. 4, A and B and Supplementary Fig. S14, A and B), suggesting that the SEZ 
should be considered as a novel potential therapeutic target in a subset of GB patients. This is 
confirmed by phylogenetic reconstruction showing different patterns of tumor evolution with the SEZ 
harboring precursor clones or clones generated during the GB growth (Fig. 5D). 
 
Gene expression profiling of SEZ reveals that different GB subtypes (6) are present within the same 
patient. The SEZ is predominantly Mesenchymal (7 patients) or Classical (2 patients). T is more 
diverse, with representation from all four subtypes (Fig. 2D). Thus it is possible to envisage a spectrum 
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of expression patterns with Mesenchymal/Classical representing proliferative diversification at the 
heart of the tumor. 
  
Previous reports suggested that proximity to the SEZ predicts a multifocal tumor phenotype and 
recurrences that arise at locations distant from the initial lesion (45). More recently it has also been 
reported that contact of the tumor mass with the SEZ correlates with shorter survival (46). To explore 
this, we isolated TICs from T and SEZ of the same patients. TICs have been described in human GB 
but no analysis based on FGMS has been performed. Our results show that in vivo both T- and SEZ-
derived cells generated tumors, however cells from T are more tumorigenic in comparison to the SEZ 
in agreement with the CNAs of the patient samples showing a trend towards a smaller number of 
aberrations in the SEZ. These data suggest that the tumorigenic potential is exacerbated when increased 
genetic alterations are acquired by the cancer genome in line with previous reports (47, 48).  
 
Since genomic and phenotypic analyses suggest that the SEZ harbors tumor cells, it is crucial to 
investigate whether there are differences in response to therapy in cells isolated from this region. It has 
been previously shown that patient-derived TICs accurately represent parent disease (27) and have 
potential application in high-throughput drug screening (28, 29). Our data reveal that TICs from T and 
SEZ of the same GBs show different patterns of response to therapies that represent the current 
standard of care (Fig. 4, A and B, Supplementary Fig. S14, A and B and Supplementary Table S5). 
This suggests that they should be targeted using different approaches. Our results also reveal that a 
clinically significant fraction of cells is resistant to current treatments. This is consistent with murine 
data (3) indicating that multi-modal stratified approaches will be essential to improve therapeutic 
responsiveness. 
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GB evolves by following poorly understood spatial and temporal dynamics arising from cells of origin  
that are yet to be defined. The presence of malignant cells in the SEZ suggests two different scenarios 
of evolution with the GB growing into the SEZ or out of this region. Our phylogenetic data indicate 
that in 4/8 patients a pool of malignant precursor clones evolved in the SEZ (Fig. 5D). Given the 
presence of neural stem cells in the adult human SEZ (49), it has been suggested that GB is derived 
from those cells (50). This concept has been investigated in mouse models (2, 38-40), but until now 
there has been no direct evidence of the contribution of SEZ cells in human gliomagenesis. We show 
that the SEZ is a reservoir of disease and could be targeted therapeutically. Consistent with this, 
preliminary evidence suggest that irradiation of the SEZ in GB patients is associated with improved 
progression-free survival (51, 52).  
 
In summary, we present a phenotypic, genomic and functional analysis of residual disease in human 
GB (Supplementary Fig. S18, A and B). Our approach together with FGMS provides a coherent 
strategy for interrogating the mechanistic basis of clinical heterogeneity in future studies. This is likely 
to further refine our understanding of the complex molecular landscape of GB, resulting in improved 
therapeutic strategies specifically aimed at targeting the SEZ. 
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Figure legends 
Figure 1. Identification of SEZ in human GB. (A) Top panel. Illustrative MRI scans of a GB in the 
right temporal lobe. Red dots indicate tissue sampling from T and SEZ. Middle panel. Peri-operative 
images of visible fluorescence from T and SEZ indicating the presence of tumor tissue. Bottom panel. 
Haematoxylin&Eosin staining of T and SEZ. Both show cardinal features of GB (high mitotic index, 
nuclear atypia, mitosis and microvascular proliferation). Scale bar, 100 μm. (B) T and SEZ tissues have 
been stained for Gfap (green), Nestin (red), CD31 (pink) and counterstained with DAPI (blue). SEZ is 
characterized by Gfap expression and high vascularization. Scale bar, 100 µm. (C) Quantitative 
analysis of Gfap-, Nestin- and CD31-positive cells in T and SEZ tissues of the same patient.  
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Figure 2. The SEZ harbors residual disease. (A) Summary of the most common putative drivers in 
GB. In 6/8 patients the SEZ contains an equal or smaller number of aberrations with respect to its 
corresponding T. Cultured cells from T and SEZ of patient sp14 have been used for comparison with 
the corresponding tissues. (B) FISH of 3 patients confirms gain of the region of chromosome 7 
including EGFR and the centromere (centr 7) in sp49 and sp58 (T and SEZ in both cases) and gain of 
the region including MET and centr 7 in sp58 and cells from sp14 (T and SEZ in both cases); as 
expected, based on copy number data, gain of MET was not observed in sp49T. Orange denotes EGFR 
or MET and green the centr 7. The single nuclei are representative of what was generally observed in 
each sample. (C) Clustering of gene expression profiles from 9 patients reveals that 5 SEZ samples 
cluster tightly together instead of with their matched T. Samples are color-coded based on their origin. 
(D) Each compartment of 9 GBs has been assigned to a previously described classifier (6): T samples 
are either Proneural, Classical, Mesenchymal or Neural and 7/9 SEZ are Mesenchymal. 
 
Figure 3. TICs can be isolated from SEZ of GB patients. (A) Cells from T and SEZ form spheres in 
serum-free medium. Magnification 100X; scale bar 50μm. (B) Left. Growth curve analysis shows that 
cells from T and SEZ are capable of long-term expansion. Right. Limiting-dilution assays reveal 
similar frequencies of sphere-formation in T and SEZ. Each data point represents the average of 
triplicates. Error bars, s.d. (C) Top. Cumulative Kaplan-Meier survival analysis of 30 animals reveals 
the tumorigenic potential of T and SEZ cells from 5 GBs. There is a statistically significant difference 
(p-value <0.05, Logrank test) between the survival of animals injected with T cells versus those 
injected with SEZ cells. Bottom. Table summarizing the number of tumors/injections and the type of 
cells used (primary or briefly cultured). (D) Haematoxylin&Eosin staining of T and SEZ cells-derived 
xenografts. Scale bar, 30 µm. 
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Figure 4. TICs from SEZ contribute to drug resistance. Cells from T and SEZ of 4 patients were 
used to evaluate response to chemotherapeutics. (A) Differential response patterns to temozolomide 
(TMZ) were observed in T and SEZ cells of the same patients. Dose escalation has little impact on 
drug-resistant cells. (B) Distinct patterns of response are observed when the assay is performed with 
Cisplatin and Cediranib. Data are shown as normalized to control. The mean normalized absorbance as 
well as the minimum (-) and maximum (+) absorbance are plotted. Asterisks indicate statistical 
significance.  
 
Figure 5. Phylogenetic reconstruction reveals different patterns of tumor evolution involving SEZ  
malignant cells. (A) Cartoon illustrating the phylogeny based on molecular clock  analysis. Non-
dividing tissues, such as heart and  brain, do not undergo mitotic events and do not accumulate 
methylation errors. Epithelial tissues, such as colon, show increased methylation with age due to the 
mitotic turnover of cells maintaining tissue homeostasis. Tumors undergo a large number of divisions 
and accumulate methylation changes in a manner proportional to the number of mitotic events. (B, C) 
Top. The IRX2 locus on chromosome 5 (in B) and the NETO1 locus on chromosome 18 (in C) have 
been validated as molecular clock loci by verifying that age-related methylation increases as a result of 
cell division in patient-derived tissues by comparing heart, brain and colon. Bottom. The graphs show 
tumor cellularity using IRX2 (in B) and NETO1 (in C) molecular clock data. The values of cellularity 
indicate no significant difference between T and SEZ. (D) Tumor phylogenies based on SEZ and 
multiple tumor mass samples (T, T1-T6) were reconstructed independently with 2 methods: copy 
number breakpoints (a) and two molecular clock loci (b, IRX2 and c, NETO1). As an example, in sp52 
the SEZ (blue) harbors cells that arise earlier than tumor mass cells (red) (sample T1 failed 
hybridization). NA= not available.  
 





